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Summary objective To recommend a cost-effective approach for the management of acute male urethritis in the
developing world, based on the ﬁndings of a theoretical study.
methods A model was developed to assess the cost-effectiveness of three urethritis management strategies
in a theoretical cohort of 1000 men with urethral syndrome. (1) All patients were treated with ceﬁxime and
doxycycline for gonococcal urethritis (GU) and nongonococcal urethritis (NGU), respectively, as
recommended by WHO. (2) All patients were treated with doxycycline for NGU; treatment with ceﬁxime
was based on the result of direct microscopy of a urethral smear. (3) All patients were treated with
cotrimoxazole or kanamycin for GU and doxycycline for NGU. Ceﬁxime was kept for patients not
responding to the ﬁrst GU treatment. Strategy costs included consultations, laboratory diagnosis (where
applicable) and drugs. The outcome was the rate of patients cured of urethritis. Cost-effectiveness was
measured in terms of cost per cured urethritis.
results Strategy costs in our model depended largely on drug costs. The ﬁrst strategy was conﬁrmed as the
most effective but also the most expensive approach. Ceﬁxime should cost no more than US$ 1.5 for the
strategy to be the most cost-effective. The second strategy saved money and drugs but proved a valuable
alternative only when laboratory performance was optimal. The third strategy with cotrimoxazole was the
least expensive but a low follow-up visit rate, poor treatment compliance or lower drug efﬁcacy limited
effectiveness. Maximizing compliance by replacing cotrimoxazole with single-dose kanamycin had the single
greatest impact on the effectiveness of the third strategy.
conclusion Our model suggested that a cost-effective approach would be to treat gonorrhoea with a
single-dose antibiotic selected from locally available products that cost no more than US$ 1.5.
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Introduction
Urethritis in men is primarily caused by gonococcal and
chlamydial infection (Holmes et al. 1999). It is well known that
prompt and effective treatment of urethritis not only prevents
complications and sequelae, but also reduces the risk of HIV
transmission (Grosskurth et al. 1995; Holmes et al. 1999).
Syndromic management of urethritis following WHO
guidelines recommends concurrent antibiotic therapy for
gonococcal and chlamydial infection (WHO 1994). The
treatment of gonococcal urethritis used to be straightforward.
However, gonococcal resistance to several antibiotics in
different parts of the world has made treatment
recommendations for gonococcal infection somewhat more
complicated. At present there is no single drug for the
treatment of gonorrhoea in the developing world that
combines efﬁcacy and low price. Ceﬁxime, ceftriaxone, and
spectinomycin are recommended by WHO as ﬁrst-line drugs
for the treatment of gonococcal urethritis, because they remain
highly efﬁcacious all over the world (Moran & Levine 1995).
However, their main drawback is their high cost.
Ciproﬂoxacin, also recommended by WHO, has become
cheaper in some countries, but resistance in South and South-
east Asia means that it can no longer be universally
recommended (WHO 1997; Bhalla et al. 1998; Ng et al. 1998;
Tapsall et al. 1998; Bhuiyan et al. 1999; Klausner et al. 1999).
Kanamycin and above all cotrimoxazole are still widely used in
Africa where they remain efﬁcacious and are considerably less
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expensive. Rather than readily endorsing the recommendation
for the most efﬁcacious (and expensive) drugs, public health
professionals in the developing world may want to identify the
most cost-effective approach towards treatment of gonococcal
infection.
Basically, STD programme managers face three options for
the treatment of gonococcal urethritis, depending on their
priorities. The ﬁrst option focuses on treatment efﬁcacy, with
patients being systematically administered the most efﬁcacious
antibiotic. It is the gold standard
1 in terms of drug efﬁcacy. A
second option aims for diagnosis speciﬁcity and drug saving,
with gonococcal infection ﬁrst conﬁrmed by direct microscopy
before treatment. The third option sets the priority on ﬁnancial
accessibility, by having gonococcal infection treated in the ﬁrst
place with an inexpensive drug. The debate between defenders
of each management strategy has usually focused either on
pharmaceutical efﬁcacy or ﬁnancial accessibility rather than
cost-effectiveness. Our objective was to assess the cost-
effectiveness of the three options by means of a simple model.
Materials and methods
The three management strategies
The ﬁrst strategy in our model, which focused on treatment
efﬁcacy, had all male patients treated for gonococcal infection
with a single oral dose of 400 mg ceﬁxime. Ceftriaxone and
spectinomycin, the other ﬁrst-choice drugs according to WHO,
require intramuscular administration and are usually even
more expensive than ceﬁxime (Management Sciences for
Health 1999). The second strategy, focusing on speciﬁcity, had
patients treated with ceﬁxime depending on the presence of
intracellular diplococci on a Gram-stained urethral smear. The
third strategy, focusing on ﬁnancial accessibility, had all
subjects treated with cotrimoxazole, 10 tablets of 480 mg daily
for 3 days or kanamycin 2 g IM stat, following WHO’s
recommendations (WHO 1991). Ceﬁxime was kept for those
who failed to respond to ﬁrst-line treatment. Our model also
had all subjects systematically treated for nongonococcal
urethritis with doxycycline 100 mg bd. for 7 days, following
WHO’s recommendation (WHO 1994). While the ﬁrst strategy
was the gold standard, the other two were potential
alternatives to be evaluated.
The model
Decision trees were developed to model the management of
gonococcal and nongonococcal infection following the three
strategies in a hypothetical cohort of 1000 male patients with
symptoms and/or signs of urethritis (Figures 1,2,3). The model
was kept simple by leaving aside the costs associated with
complications in men and in their female partners.
Transmission and complication rates were indeed assumed to
remain constant in the absence of any intervention. Two
additional assumptions were made to limit the complexity of
the decision trees. First, patients not infected with gonorrhoea
were considered correctly diagnosed by microscopy (i.e. no
false positives) and therefore not treated. Secondly, patients not
compliant with multidose antibiotic therapy, be it for
gonococcal or chlamydial infection, were considered lost and
not cured.
The cost of each strategy included consultations,
microscopic examination where applicable, and antibiotics
for gonococcal and chlamydial infection. The costs of
Patients with
urethral syndrome,
treated with
cefixime and
doxycycline
Not infected,
unnecessarily treated
GU + NGU
NGU
GU
Infected
0.81
0.19
0.5
0.3
0.2
1.0
0.74
0.26
0.26
0.74
cured
compliant,
cured
not compliant,
not cured
not compliant,
not cured
compliant, cured
Figure 1 Strategy 1. The gold standard.
1 ‘Gold standard’ refers to the generally preferred strategy.Tropical Medicine and International Health volume 5 no 9 pp 640–647 september 2000
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consultation and laboratory were based on government
sector’s salaries and workload in several of the poorest
countries in sub-Saharan Africa, Latin America and Asia
2.
Healthcare provider and laboratory technician’s salaries were
set at US$ 75 and 100, respectively, for 460 consultations per
month. Laboratory costs, including consumables and
reagents, were US$ 0.51 per test. Unit costs thus amounted to
US$ 0.16 for the medical consultation and US$ 0.73 for
laboratory testing. The average cost of generic antibiotics
was obtained from the International Drug Price Indicator
Guide (>Management Sciences for Health 1999), and that of
Patients with urethral
syndrome treated
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Not infected
correct lab test,
not treated
GU +
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Infected
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0.3
0.2
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correct lab test,
treated for
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correct lab test,
treated for
GU + NGU 0.95
GU
correct lab test,
treated for NGU
NGU
incorrect lab test,
treated for
GU + NGU
incorrect lab test,
not treated
0.02
0.95
0.03
incorrect lab test,
treated only for NGU
or not treated, not
cured
incorrect lab test,
treated for NGU
or not treated,
not cured
1.0
cured
0.34
0.66
treated for GU
+ NGU at
control visit
lost,
not cured
0.74
0.26
not compliant,
not cured
compliant, cured
0.74
0.26
not compliant,
not cured
compliant, cured
0.34
0.66
treated for GU
+ NGU at
control visit
lost,
not cured
not compliant,
not cured
compliant, cured
0.74
0.26
0.34
0.66
treated for GU
+ NGU at
control visit
lost,
not cured
0.26
0.74
not compliant,
not cured
compliant, cured
0.26
0.74
not compliant,
not cured
compliant, cured
1.0
cured
Figure 2 Strategy 2. Based on microscopic examination of a urethral smear.
2 African countries from which data were obtained included Burkina
Faso, Congo, Ghana, Mali and Tchad. Latin American countries
included Ecuador, Haiti, and Nicaragua. Asian countries included
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ceﬁxime was provided by an international nonproﬁt drug
distributor in the Netherlands. Drug costs were increased by
30% to include transport and handling. Thus the values used
in the model were US$ 4.0, 0.9, 0.7 and 0.6, respectively, for a
full course of ceﬁxime, kanamycin, cotrimoxazole and
doxycycline. The outcome indicator for each strategy was the
rate of patients cured of urethritis. The cost per cured
urethritis was obtained by dividing the management cost for
1000 patients by the number of cured patients.
Rates and sensitivity analysis
Table 1 lists the rates ascribed to some of the variables in the
model. These were found in the published literature. The
follow-up visit rate was estimated by Delphi survey performed
for this study. Factors likely to vary widely across countries or
types of setting, such as follow-up visit rate, laboratory
performance and antimicrobial resistance were submitted to a
sensitivity analysis to assess their impact on the model.
Results
Baseline performance
The baseline performance of the three strategies is shown in
Table 2. Strategy costs depended largely on the cost of drugs.
The gold standard strategy yielded the highest outcome at the
highest cost. Following our model the total cost of the
strategy was US$ 4800 to effectively treat 87% of the 810
infected patients, or US$ 6.8 per cured urethritis. The 105
subjects (13%) not cured were those who had ‘failed’ to
comply with their doxycycline treatment. Strategy 2 was
nearly as effective when laboratory performance was optimal.
Despite the additional cost of microscopic examination,
limiting the use of ceﬁxime resulted in a total cost of
US$ 4000 to cure 85% of infected patients. Strategy 3 was the
least expensive option, with a total cost of US$ 1,700, but the
rate of cured patients did not exceed 64%. Table 3 shows the
inﬂuence of changing some of the variables on the cost-
effectiveness of strategies 2 and 3.
Patients with
urethral syndrome,
treated with
cotrimoxazole and
doxycycline
Not infected,
unnecessarily treated
GU + NGU
NGU
GU
Infected
0.81
0.19
0.5
0.3
0.2
0.26
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0.26
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cured
not compliant,
lost, not cured
not compliant,
not cured
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compliant 0.74
not compliant,
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not cured
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0.7
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0.66
treated with cefixime
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not cured
0.3
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0.7
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Figure 3 Strategy 3. First treatment with cotrimoxazole. Ceﬁxime reserved for returning failure cases.Tropical Medicine and International Health volume 5 no 9 pp 640–647 september 2000
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Influence of laboratory performance on cost-effectiveness
The performance of strategy 2 clearly depended on the
quality of microscopic examination. Both the effectiveness
and total cost decreased, though not markedly, when the
sensitivity and speciﬁcity were arbitrarily set at 80% and
85%, then 60% and 70%, respectively. However, the cost per
individual patient increased since the number of cured
patients dropped faster than the total cost.
Influence of the follow-up visit rate
Keeping the gold standard in mind, we ﬁrst modiﬁed the
follow-up visit rate in strategy 3 to observe its effect on cost-
effectiveness. Even after almost tripling the follow-up visit
rate, the effectiveness only increased from 64% to 72%.
While the total cost rose as a consequence of the greater
number of patients treated with ceﬁxime, the cost per cured
urethritis was only marginally increased.
Influence of drug efficacy
When cotrimoxazole efﬁcacy was maximized (the other
variables being unchanged), 599 patients (74%) were cured at
an individual cost of US$ 2.5. In the 100%-efﬁcacy scenario,
the effectiveness was basically limited by the 74% compliance
with the multidrug regimen. We also looked at the
consequence of replacing cotrimoxazole with single-dose
kanamycin. At a 70% efﬁcacy kanamycin cured 74% of the
cohort at a cost of US$ 3.2 per cured patient. As the efﬁcacy
of the drug went up, the percentage of cured patients went up
and the costs went down. With kanamycin efﬁcacy at 100%,
strategy 3 matched strategy 1 in terms of efﬁcacy but at one
third of the cost.
Our ﬁndings remained unchanged even after raising the
unit costs for consultation from US$ 0.16 to 0.48, and for
laboratory testing from US$ 1.17 to 1.66. This actually meant
tripling labour costs or dividing workload by three. Only
when labour costs were multiplied by six did strategy 1
Baseline Sensitivity analysis
(%) (%)
Subjects with symptoms and/or 
signs of urethritis, not infected 19*
Infected patients with 
gonococcal infection 50
nongonococcal infection 30
both 20†
Compliance with 
multidose treatment 74‡
single-dose treatment 100
Follow-up visit rate 34 50 70 90
Validity of the Gram stain§
sensitivity 95 80 60
speciﬁcity 95 85 70
Gonococcal resistance to antibiotics
ceﬁxime 0
cotrimoxazole 30 20 10 0
kanamycin 30 20 10 0
* Kuvanont et al. (1989); Mayaud et al. (1992)
† Louis et al. (1993)
‡ Jordan (1989); Katz et al. (1991); Homedes & Ugalde (1993)
§ Goodhart et al. (1982); Landis et al. (1988)
Table 1 Values at baseline and for sensitivity
analysis
Table 2 Baseline performance of the three strategies
Strategy N (%) of cured Total cost Cost ($) per
urethritis * (US$) cured urethritis
1 705 (87) 4800 6.8
2 688 (85) 4000 5.8
3 516 (64) 1700 3.3
* Percentages are calculated from a total of 810 patients considered
really infected.Tropical Medicine and International Health volume 5 no 9 pp 640–647 september 2000
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become less expensive than strategy 2, as labour costs
associated with strategy 2 surpassed drug savings. Likewise,
our ﬁndings were unaffected by modifying the rates of
gonococcal, chlamydial or mixed infection in the model.
Finally, we calculated the price ceﬁxime should ideally not
exceed in order to have strategy 1 comparing favourably in
terms of cost with the least expensive strategy. At US$ 1.5 per
ceﬁxime treatment, the total cost of the ﬁrst strategy dropped
to the baseline cost of the third strategy, i.e. US$ 2,300, or
slightly less than US$ 3.3 per cured urethritis.
Discussion
In short, the gold standard strategy was, as expected, both
the most effective and the most expensive approach. Strategy
2 matched the gold standard only when laboratory
performance was optimal. Falling laboratory performance led
to effectiveness falling similarly. Strategy 3 using
cotrimoxazole was the least expensive, but was limited by
treatment compliance even at the highest drug efﬁcacy. With
kanamycin, the effectiveness of strategy 3 depended mainly
on drug efﬁcacy. At 100% drug efﬁcacy, it matched the gold
standard in terms of effectiveness, at a much lower cost.
These ﬁndings conﬁrm what most public health decision-
makers already knew intuitively, but they pointed to a few
additional facts. The gold standard strategy is expensive
when third-generation cephalosporins have to be
recommended. At US$ 4 per treatment with ceﬁxime, drug
costs dwarf labour costs. In a country like Cambodia, a
reasonable estimate of the cost of procuring drugs for the
syndromic management of STDs at primary encounter level
nationwide amounted to nearly US$ 3 million per year, with
ceﬁxime representing most of it. The national government is
obviously unable to face such an enormous cost. Since
patients are equally unable to afford treatment, the best drug
for the treatment of gonococcal infection remains
Strategy 2
Performance of microscopic examination
N (%) Total cost  Cost (US$) per 
Sensitivity Speciﬁcity cured cases (USUS$) cured urethritis
95 95 688 (85) 4000 5.8
80 85 638 (79) 3850 6.0
60 70 572 (71) 3650 6.4
Strategy 3
Impact of follow-up visit rate
N (%) of cured Total cost Cost (USUS$) per
Return rate urethritis (USUS$) cured urethritis
34% 516 (64) 1700 3.3
50% 535 (66) 1800 3.4
70% 562 (69) 1950 3.5
90% 587 (72) 2050 3.5
Impact of cotrimoxazole efﬁcacy
N (%) of cured Total cost Cost (US$) per
Drug efﬁcacy urethritis (US$) cured urethritis
70% 516 (64) 1700 3.3
80% 544 (67) 1650 3.0
90% 572 (71) 1600 2.8
100% 599 (74) 1500 2.5
Impact of kanamycin efﬁcacy
N (%) of cured Total cost Cost (US$) per
Drug efﬁcacy urethritis (US$) cured urethritis
70% 601 (74) 1950 3.2
80% 635 (78) 1900 3.0
90% 670 (83) 1800 2.7
100% 705 (87) 1700 2.4
Table 3 Impact on model outcome of
performance of microscopic examination,
follow-up visit rate and gonococcal
antimicrobial resistanceTropical Medicine and International Health volume 5 no 9 pp 640–647 september 2000
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inaccessible to most. However, in some African countries,
such as Côte d’Ivoire or South Africa where the efﬁcacy of
quinolones remains and where national governments have
managed to obtain them at around US$ 1.5, strategy 1 with
quinolones is deﬁnitely the preferred option.
Strategy 2 seems to offer an attractive alternative to the
gold standard especially where labour costs (and thus the cost
of laboratory work) are much lower than imported drugs.
However, our model showed that this option is valid only
when laboratory performance is optimal. Its advantages
become marginal when the quality of laboratory work falls
below this level.
When increasing the follow-up visit rate in Strategy 3 we
were surprised that its impact was so limited. However, our
model revealed that only 90 patients with gonorrhoea and 36
with mixed infection were likely to return for a follow-up visit.
Thus increasing the follow-up visit rate from 34 to 90% added
only 71 subjects to the total number of cured patients. Our
model clearly suggested that efforts to bring patients back to
the consultation would have limited beneﬁt. Improving the
efﬁcacy of cotrimoxazole in Strategy 3 resulted in increased
effectiveness and lower costs. However, our model highlighted
the importance of treatment compliance. Even at maximum
efﬁcacy, the total rate of cured patients with cotrimoxazole as
the ﬁrst line drug (599) was just under the rate obtained with a
single administration drug such as kanamycin at 70% efﬁcacy
(601). Our model suggested that the multiple-dose
cotrimoxazole regimen, however efﬁcacious and inexpensive,
should no longer be recommended when there is a single
administration alternative that does not cost more than
US$ 1.5.
Which single-dose products could be used to treat
gonococcal infection at an acceptable cost in the developing
world? Unfortunately there is no single inexpensive drug. Since
gonococcal resistance to antibiotics varies extensively across
countries, local assessment of drug efﬁcacy has become
mandatory and options vary. For example, the single
administration of amoxycillin and clavulanic acid is currently
the preferred option in Kenya. Gentamycin is recommended in
Malawi and kanamycin in Zimbabwe.
Our theoretical exercise has limitations. Only a few variables
were considered in the model. In order to keep it simple,
patients not compliant with multiple-dose drug regimens
(cotrimoxazole or doxycycline) were considered lost and not
cured. The rate of transmission of infection to female partners
as well as the rate of complications were deemed constant and
not taken into account. Costs included only drugs,
consultations and microscopic examination where applicable.
Extra costs associated with improving the follow-up visit rate
or with monitoring gonococcal antimicrobial resistance were
not considered. Low labour costs are representative of many
countries in the developing world, but do not necessarily apply
worldwide. Finally the issue of intramuscular administration
vs. oral intake was not considered.
Nevertheless, by translating concepts into numbers our
model emphasized the advantages and limitations of the three
strategies, and suggested the following two conclusions. First,
the simplest and most cost-effective approach for public
health decision-makers might be to negotiate the purchase of
WHO’s recommended drugs at around US$ 1.5 per
treatment. Alternatively, they might try to identify an
efﬁcacious single-dose product from among inexpensive
antibiotics, based on local gonococcal resistance ﬁndings.
Secondly, cotrimoxazole should be abandoned for the
treatment of gonococcal infection, especially if there is a
single administration alternative that does not cost more than
US$ 1.5.
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